Liposomal ciprofloxacin: Phase II data

In an open-label, New Zealand and Australian Phase II trial (ARD-3100-0702), once-daily inhaled liposomal ciprofloxacin met the primary endpoint of a significant change from baseline in sputum P. aeru...